Table 9 Macroeconomic (ROI) for ranibizumab therapy for neovascular AMD using the societal cost perspective, combined-eye model
Cost perspective | Direct ophthalmic medical cost per patient | Annual # of cases | Total direct ophthalmic medical costs | Net cost/case with direct ophthalmic costs | 12-year financial gain |
|---|---|---|---|---|---|
MARINA—costs off-setting the s direct ocular medical costs | $79,056 | 178,000 | $14.1 billion | (−$282,517) | $50.2 billion |
MARINA GDP gain | $79,056 | 178,000 | $14.1 billion | (−$165,842) | $29.5 billion |